Immune checkpoint inhibitors demonstrate an emerging therapeutic role in the management of perivascular epithelioid cell tumors (PEComas), a rare subset of soft tissue sarcomas.
Do immune checkpoint inhibitors improve outcomes in patients with PEComas?
This paper discusses the emerging role of immune checkpoint inhibitors in the treatment of rare perivascular epithelioid cell tumors (PEComas).
Absolute Event Rate: 0% vs 0%
Perivascular epithelioid cell tumors (PEComas) constitute a rare subset of mesenchymal neoplasms within the broader category of soft tissue sarcomas (STS), affecting around 0.12 to 0.24 per million...
Assi et al. (Wed,) reported a other. Immune checkpoint inhibitors demonstrate an emerging therapeutic role in the management of perivascular epithelioid cell tumors (PEComas), a rare subset of soft tissue sarcomas.